Evidence map›Paper›PMID 41808619›Full record

ArticleJournal of the National Cancer Institute2026

Divergent effects of PLA2G7 on prostate cancer biochemical recurrence in European American and African American men.

Channing J Paller, Shuanzeng Wei, Megan Schumacher, Daniel Rabizadeh, Yu-Ching Hsu, Changxue Lu, Yidong Chen, Yuezhou Jing, Bruce J Trock, Mayuko Kanayama and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Channing J PallerDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-3658-1858
Shuanzeng WeiDepartment of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA.ORCID 0000-0002-0441-6973
Megan SchumacherDepartment of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0009-0008-0973-0639
Daniel RabizadehDepartment of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0009-0006-9570-2081
Yu-Ching HsuDepartment of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Changxue LuDepartment of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-7565-8796
Yidong ChenDepartment of Population Health Sciences, the University of Texas Health San Antonio, San Antonio, TX, USA.
Yuezhou JingDepartment of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Bruce J TrockDepartment of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-3529-9295
Mayuko KanayamaDepartment of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-1947-6311
Stefan AmbsLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID 0000-0001-7651-9309
Diana M StafforiniHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0003-3607-2981
William B IsaacsDepartment of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-6599-6775
George J NettoDepartment of Pathology and Lab Med, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-3915-9134
Tamara L LotanDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-0494-9067
Angelo M De MarzoDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-4847-5307
Elizabeth A PlatzDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-3676-8954
Jun LuoDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-1414-473X

Funding

Department of Defense Prostate Cancer Research Program W81XWH-22-2-0024National Institutes of Health Cancer Center Support P30CA006973Patrick C Walsh Prostate Cancer Research Fund
6 · The paper itself

Abstract

backgroundIdentification and characterization of prostate tumor markers differentially expressed in European American (EA) men vs African American (AA) men has been one of the focus areas positioned to understand and address prostate cancer disparity in the US. Whereas some genes are differentially expressed, validation studies are limited, and the impact of these expression differences on recurrence risk remains unclear.

methodsThis study focused on phospholipase A2 group 7 (PLA2G7) in prostate cancer surgical specimens from EA and AA patients. A nested case-control study was conducted to evaluate the prognostic value of the PLA2G7 protein while controlling for age, stage, and Gleason, followed by re-analysis of a published dataset of 556 EA and 596 AA prostate cancer patients. Expression signatures correlated with PLA2G7 were investigated in both patient populations.

resultsPLA2G7 was more frequently overexpressed in EA tumors than AA tumors, and higher tumor-specific PLA2G7 expression was associated with divergent outcomes: lower biochemical recurrence risk in EA men but elevated risk in AA men. Expression in noncancer tissues showed no prognostic value. Whereas androgen response signatures were consistently enriched in high-PLA2G7 tumors across both groups, immune and inflammatory response gene sets showed opposite enrichment trends between AA and EA men.

conclusionThis study represents the first identification and validation of a tumor-specific marker that is both differentially expressed between prostate cancers in AA and EA men and demonstrates opposite prognostic effects based on self-reported race/ethnicity. The findings emphasize the importance of evaluating prostate tumor markers across diverse geographic ancestries.

Indexed as

Biomarkers, TumorBlack or African AmericanNeoplasm Recurrence, LocalPhospholipases A2Prostatic NeoplasmsWhite1-Alkyl-2-acetylglycerophosphocholine EsteraseAgedCase-Control StudiesGene Expression ProfilingHumansMaleMiddle AgedNeoplasm GradingPrognosisProstate-Specific Antigen1-Alkyl-2-acetylglycerophosphocholine EsteraseBiomarkers, TumorPhospholipases A2PLA2G7 protein, humanProstate-Specific Antigen

Identifiers

PMID41808619
PMCPMC13247341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.